key: cord-0726569-9qewqavk
authors: Hall, Elisha; Morales, Sarah; Wolicki, JoEllen; Schillie, Sarah
title: COVID‐19 vaccine inquiries regarding children ages 5–11 years received by NIP‐INFO
date: 2022-04-12
journal: Public Health Nurs
DOI: 10.1111/phn.13079
sha: 80ce1dbb2d06e9210a6dace72d9fafae2a498a3e
doc_id: 726569
cord_uid: 9qewqavk

We describe COVID‐19 immunization inquiries regarding children age 5–11 years received by NIP‐INFO, the Centers for Disease Control and Prevention's (CDC's) e‐mail immunization inquiry service for health care professionals, at the launch of vaccination efforts for this age group, using descriptive qualitative analysis. From November 2 through November 30, 2021, NIP‐INFO responded to 154 questions regarding COVID‐19 vaccination for 5–11‐year‐old children. The most common questions related to formulation and dosage (39.6%), vaccination schedule (14.3%), CDC's educational materials for health care professionals (9.1%), and vaccine safety (8.4%); 16.2% of questions across all inquiry categories related to a vaccination error. We discuss CDC guidance related to the most common inquiries to inform further pediatric COVID‐19 vaccination efforts, including future vaccination of younger pediatric age groups, which will be important to help to curb this pandemic.

On October 29, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine for children age 5-11 years (FDA, 2021b 

Findings of this study reveal key themes that characterize questions providers and the public raise as COVID-19 vaccine is expanded to younger age groups. Not surprisingly, questions regarding formulation and dosage accounted for the majority of questions regarding Pfizer-BioNTech COVID-19 vaccine for 5-11-year-olds, and errors accounted for 23.0% of formulation and dosage questions. Important differences exist for COVID-19 vaccine formulation and dosage between the 12 years or older age group and the 5-11 years age group. The formulation for children age 5-11 years is supplied in a vial with an orange cap; each 0.2 ml dose contains 10 µg of modified mRNA. The formulation for persons age 12 years or older is supplied in a vial with a purple cap; each 0.3 mL dose contains 30 µg of modified mRNA (FDA, 2021c). Since the time the pediatric formulation was authorized, another adolescent and adult formulation has become available (gray cap).

Common themes among the formulation and dosage inquiries related to using the 12 years or older formulation or dosage for an 11-

year-old whose weight was large for their age, or vice versa. In contrast to many pediatric medications, vaccine dosages (for COVID-19

vaccines and other routinely recommended vaccines) are based on age and not weight (Hall et al., 2021; Kroger et al., 2021 (Kroger et al., 2021) . Another common question related to the 4-day grace period. As with routine immunizations, a COVID-19 vaccine dose administered within 4 days earlier than the recommend interval does not need to be repeated. However, the 4day grace period should not be used to prospectively schedule doses (CDC, 2021; Kroger et al., 2021) .

Questions regarding coadministration of COVID-19 vaccines with other vaccines are especially relevant for children, particularly younger children, as coadministration of all vaccines for which a person is eligible increases the probability that a person will be up to date with recommended vaccinations (Hall et al., 2021; Kroger et al., 2021; Schilling et al., 2015) . 

The authors wish to disclose that they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Research data are not shared.

Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. U.S. Department of Health & Human Services

Centers for Disease Control and Prevention. Public Health Foundation

General best practice guidelines for immunization: Best practices guidance of the advisory committee on immunization practices (ACIP). Centers for Disease Control and Prevention

Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines

Characteristics and clinical outcomes of children and adolescents aged <18 years hospitalized with COVID-19-Six hospitals

COVID-19 vaccine inquiries regarding children ages 5-11 years received by NIP-INFO